Evidence map›Paper›PMID 31858384›Full record

ArticleHormones & cancer2020

A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification.

Kaan Oktay, Ashlie Santaliz-Casiano, Meera Patel, Natascia Marino, Anna Maria V Storniolo, Hamdi Torun, Burak Acar, Zeynep Madak Erdogan

Open access · bronzeAbstract read
In one paragraph

Article in Hormones & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. PFAS and their association with the increased risk of cardiovascular disease in postmenopausal women.Toxicological sciences : an official journal of the Society of Toxicology · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Of Screening, Stratification, and Scores.Journal of personalized medicine · 2021
    Review
  15. Article
  16. Article
  17. Liquid biopsies and cancer omics.Cell death discovery · 2020
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Kaan OktayVAVlab, Electrical & Electronics Engineering Department, Bogazici University, Istanbul, Turkey.
Ashlie Santaliz-CasianoDivision of Nutritional Sciences, University of Illinois Urbana-Champaign, Urbana, IL, USA.
Meera PatelSusan G. Komen Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN, USA.
Natascia MarinoSusan G. Komen Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN, USA.
Anna Maria V StornioloSusan G. Komen Tissue Bank at the IU Simon Cancer Center, Indianapolis, IN, USA.
Hamdi TorunFaculty of Engineering and Environment, University of Northumbria, Newcastle upon Tyne, UK.
Burak AcarVAVlab, Electrical & Electronics Engineering Department, Bogazici University, Istanbul, Turkey.
Zeynep Madak ErdoganDivision of Nutritional Sciences, University of Illinois Urbana-Champaign, Urbana, IL, USA. zmadake2@illinois.edu.ORCID 0000-0003-2607-1643
Indiana University Health · USBoğaziçi University · TRUniversity of Illinois Urbana-Champaign · USNorthumbria University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the second leading cause of cancer mortality among women. Mammography and tumor biopsy followed by histopathological analysis are the current methods to diagnose breast cancer. Mammography does not detect all breast tumor subtypes, especially those that arise in younger women or women with dense breast tissue, and are more aggressive. There is an urgent need to find circulating prognostic molecules and liquid biopsy methods for breast cancer diagnosis and reducing the mortality rate. In this study, we systematically evaluated metabolites and proteins in blood to develop a pipeline to identify potential circulating biomarkers for breast cancer risk. Our aim is to identify a group of molecules to be used in the design of portable and low-cost biomarker detection devices. We obtained plasma samples from women who are cancer free (healthy) and women who were cancer free at the time of blood collection but developed breast cancer later (susceptible). We extracted potential prognostic biomarkers for breast cancer risk from plasma metabolomics and proteomics data using statistical and discriminative power analyses. We pre-processed the data to ensure the quality of subsequent analyses, and used two main feature selection methods to determine the importance of each molecule. After further feature elimination based on pairwise dependencies, we measured the performance of logistic regression classifier on the remaining molecules and compared their biological relevance. We identified six signatures that predicted breast cancer risk with different specificity and selectivity. The best performing signature had 13 factors. We validated the difference in level of one of the biomarkers, SCF/KITLG, in plasma from healthy and susceptible individuals. These biomarkers will be used to develop low-cost liquid biopsy methods toward early identification of breast cancer risk and hence decreased mortality. Our findings provide the knowledge basis needed to proceed in this direction.

Indexed as

Biomarkers, TumorBreast NeoplasmsFemaleHumansRisk AssessmentBiomarkers, TumorBreast cancer riskCirculating biomarkerFeature selectionLiquid biopsyMachine learning

Identifiers

PMID31858384
PMCPMC10355241
OpenAlexW2994875918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.